Centrose LLC
This article was originally published in Start Up
Executive Summary
Centrose's automated sugar synthesis platform CarboConnect can quickly and economically synthesize drugs with a wide variety of natural and unnatural sugars attached to them. The inspiration came from sugars found in natural products. Many of the antibiotics produced by microorganisms and plants contain sugars, but they are structurally different from sugars found in animal physiology. The company has already completed some proof-of-concept studies on derivative drugs in which unnatural sugars increased potency and in some cases changed the mechanism of action.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Approaches to Neuropathic Pain," features profiles of Aestus Therapeutics, Arcion Therapeutics and Spinifex Pharmaceuticals. Plus these Start-Ups Across Health Care: Centrose, Semprus BioSciences and Voyage Medical.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Approaches to Neuropathic Pain," features profiles of Aestus Therapeutics, Arcion Therapeutics and Spinifex Pharmaceuticals. Plus these Start-Ups Across Health Care: Centrose, Semprus BioSciences and Voyage Medical.
Glycobiology's Second Wave
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.